NCT00608907已完成1 期
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 9
- 主要终点
- Area Under the Plasma Concentration-time Curve (AUC) 0-72 Hours
研究概览
简要总结
The primary purpose of this Phase I study is to evaluate the effect of the co-administration of CYP3A4 inducers on the pharmacokinetics profile of VELCADE (bortezomib). Rifampicin will be used to assess the effect of a strong CYP3A4 inducer and dexamethasone to assess the effect of a relatively weak inducer. This study is also to evaluate the impact of CYP3A4 inducers on the pharmacodynamics (PD) of VELCADE and the safety profile of VELCADE.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female of at least 18 years of age.
- •Has documented relapsed or refractory multiple myeloma or NHL following prior anti-neoplastic treatment.
- •Female patients must be post menopausal for at least 1 year (must not have had a natural menses for at least 12 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; have a negative serum β-HCG or a negative urine pregnancy test at screening. (an alternative to oral contraceptives should be used if the patient is randomized to Arm B with rifampicin).
- •Male patients must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study.
- •Must be able to swallow capsules/tablets whole (without chewing, crushing, or opening).
- •Agree to refrain from the use of any methylxanthine-containing products, including caffeine (e.g., chocolate bars or beverages, coffee, teas, or colas), on Day 11 of Cycles 2 and
- •Agree to refrain from the use of any products containing nicotine, alcohol, quinine, grapefruit juice, or Seville oranges from 7 days before the first administration of VELCADE through completion of the 72-hour PK blood sample collection (post Day 11 VELCADE dose) in Cycle 3.
排除标准
- •Diagnosis or treatment of a malignancy other than multiple myeloma or NHL within 1 year of randomization, or who have previously been diagnosed with a malignancy other than multiple myeloma or NHL and have any radiographic or biochemical marker evidence of malignancy.
- •History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, psychiatric, or metabolic disturbances.
- •Known or suspected hypersensitivity or intolerance to rifampicin and/or other antibiotics, corticosteroids, boron or mannitol.
- •Peripheral neuropathy or neuropathic pain Grade 2 or higher.
- •Preplanned surgery or procedures that would interfere with the conduct of the study or major surgery within 2 weeks before randomization.
- •History of disallowed therapies:
- •Prior treatment with VELCADE.
- •Any drugs or agents that inhibit (e.g., cimetidine, erythromycin, fluoxetine, ketoconazole, paroxetine) or induce (e.g., carbamazepine, glucocorticoids, phenobarbital, phenytoin, St. John's Wort) CYP2C19 or CYP3A4 within 28 days before the first administration of VELCADE.
- •Any exposure to rifampicin or corticosteroids within 28 days of screening.
- •Have received an investigational agent or used an investigational medical device within 28 days before the planned start of treatment. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.
- •Female patient who is pregnant or breastfeeding.
- •Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
研究组 & 干预措施
VELCADE
Experimental
Control arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle.
干预措施: bortezomib (Drug)
VELCADE + rifampicin
Experimental
Treatment Arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3.
干预措施: bortezomib, rifampicin (Drug)
VELCADE + dexamethasone
Experimental
Treatment arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3.
干预措施: bortezomib, dexamethasone (Drug)
结局指标
主要结局
Area Under the Plasma Concentration-time Curve (AUC) 0-72 Hours
时间窗: Cycle 3 day 14 (72 hours post last dose)
次要结局
未报告次要终点
研究者
研究点 (9)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 CoinfectionHepatitis C Virus InfectionNCT02480712Gilead Sciences107
已完成
3 期
Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)Pneumococcal DiseaseNCT04633226Merck Sharp & Dohme LLC58
已完成
3 期
Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)Hereditary Angioedema (HAE)NCT04180163Shire12
已完成
3 期
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus InfectionHepatitis C Virus InfectionNCT02722837Gilead Sciences119
已完成
3 期
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) InfectionHepatitis C Virus InfectionNCT03074331Gilead Sciences130